These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 16797393

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
    Lezaic V, Pejanovic S, Kostic S, Pljesa S, Dimkovic N, Komadina L, Jovanovic D, Marinkovic J, Djukanovic L.
    Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
    [Abstract] [Full Text] [Related]

  • 28. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
    Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S.
    Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
    [Abstract] [Full Text] [Related]

  • 34. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients.
    Zanos S, Mitsopoulos E, Sakellariou G.
    Ren Fail; 2005 Jan; 27(2):163-9. PubMed ID: 15807180
    [Abstract] [Full Text] [Related]

  • 35. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 36. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
    Martin KJ, González E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S57-63. PubMed ID: 11689389
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Stricter criteria increase the validity of a quick intraoperative parathyroid hormone assay in primary hyperparathyroidism.
    Lupoli GA, Fonderico F, Panico A, Del Prete M, Marciello F, Granieri L, Manguso F, Misso C, Marzano LA, Lupoli G.
    Med Sci Monit; 2009 Mar; 15(3):CR111-6. PubMed ID: 19247241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.